Disruptions caused by the coronavirus pandemic depressed sales at Roche in the first nine months of the year but the company responded to the health crisis with the launch of new diagnostics and a partnership with Regeneron Pharmaceuticals Inc to develop an antibody treatment for the disease. In the third quarter, Roche received six medicine approvals in the US, the EU and Japan.
